| Clinical feature |
No of cases |
P16 Unmethylated |
% |
P16 Methylated |
% |
P value |
| Patients |
200 |
116 |
58% |
84 |
42% |
0.0001 |
| Controls |
25 |
23 |
92% |
2 |
8% |
| P16 promoter methylation Gender |
| Males |
128 |
76 |
59.4% |
52 |
40.6% |
0.7 |
| Female |
72 |
40 |
55.6% |
32 |
44.4% |
| P16 promoter methylation with stage |
| CP-CML |
81 |
60 |
74% |
21 |
26% |
0.0001 |
| AP-CML |
54 |
31 |
47.4% |
23 |
42.6% |
| BC-CML |
65 |
25 |
38.5% |
40 |
61.5% |
| P16 promoter methylation with BCR-ABL transcripts |
| a2b2 |
59 |
31 |
52.5% |
28 |
47.4% |
0.5 |
| a2b3 |
124 |
64 |
51.6% |
60 |
48.3% |
| a2b2/ a2b3 |
17 |
11 |
64.7% |
6 |
35.2% |
| P16 promoter methylation with type of therapy |
| Imatinib |
200 |
116 |
58% |
84 |
42% |
0.0001 |
| Dasatinib |
10 |
00 |
00 |
10 |
100% |
| P16 promoter methylation and age |
| Age >45 |
71 |
47 |
66.1% |
24 |
33.8% |
0.08 |
| Age <45 |
129 |
69 |
53.4% |
60 |
46.5% |
| P16 promoter methylation and molecular responses |
| MMR |
50 |
35 |
70% |
15 |
30% |
0.04 |
| No MR |
150 |
81 |
59.4% |
69 |
46% |
| P16 promoter methylation and haematological responses. |
| MHR |
30 |
24 |
80% |
6 |
20% |
0.02 |
| Minor HR |
46 |
26 |
56.5% |
20 |
43.5% |
| No HR |
124 |
66 |
53.2% |
58 |
46.8% |
| P16 promoter methylation and Thrombocytopenia |
| Thrombocytopenia |
100 |
42 |
42% |
58 |
58% |
<0.0001 |
| No Thrombocytopenia |
100 |
74 |
74% |
26 |
26% |
